Chapter 23. Therapeutic Control of Androgen Action
- 1 January 1994
- book chapter
- Published by Elsevier
- Vol. 29, 225-234
- https://doi.org/10.1016/s0065-7743(08)60736-8
Abstract
No abstract availableThis publication has 128 references indexed in Scilit:
- Microsatellite Mutation (Cag24→18) in the Androgen Receptor Gene in Human Prostate CancerBiochemical and Biophysical Research Communications, 1994
- Brain 5α-Reductase: Cellular, Enzymatic, and Molecular Perspectives and Implications for Biological FunctionMolecular and Cellular Neuroscience, 1993
- EventsComputer Fraud & Security Bulletin, 1993
- Threonine on Amino Acid Position 868 in the Human Androgen Receptor Is Essential for Androgen Binding Specificity and Functional ActivityBiochemical and Biophysical Research Communications, 1993
- Finasteride: A slow-binding 5.alpha.-reductase inhibitorBiochemistry, 1993
- The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasiaThe Prostate, 1993
- Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapyZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Androgen receptor gene expression in the rat central nervous system: Evidence for two mRNA transcriptsMolecular and Cellular Neuroscience, 1991
- Steroid binding to synaptic plasma membrane: Differential binding of glucocorticoids and gonadal steroidsThe Journal of Steroid Biochemistry and Molecular Biology, 1983
- Androgen receptor binding and androgenicity of methylated 4-ene-3-ketosteroids having no 17-hydroxy groupThe Journal of Steroid Biochemistry and Molecular Biology, 1979